Thoratec's Reduce Driveline Trauma Through Stabilization and Exit Site Management Study (RESIST)
Reduce Driveline Trauma Through Stabilization and Exit Site Management (RESIST) Pilot Study Protocol
Sponsor: Abbott Medical Devices
This observational or N/A phase trial investigates Left Ventricular Assist Device and Percutaneous Lead Management and is currently completed. Abbott Medical Devices leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jul 2022 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Jul 2022 [monthly]
Completed
-
Feb 2019 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
- Thoratec Corporation
For direct contact, visit the study record on ClinicalTrials.gov .